← Back to Search

Other

AB521 - Sequence BCA for Healthy Subjects (ARC-28 Trial)

Phase 1

Waitlist Available

Research Sponsored by Arcus Biosciences, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up predose, up to 168 hours postdose

Awards & highlights

ARC-28 Trial Summary

This trial studies how a drug is absorbed into the body when taken as a tablet or capsule, and how food affects the tablet form.

ARC-28 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ predose, up to 168 hours postdose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~predose, up to 168 hours postdose

This trial's timeline: 3 weeks for screening, Varies for treatment, and predose, up to 168 hours postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Apparent Total Plasma Clearance (CL/F)

Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F)

Area Under the Plasma Drug Concentration-Time Curve (AUC)

+3 more

Secondary outcome measures

Number of Participants With Adverse Events

ARC-28 Trial Design

3Treatment groups

Experimental Treatment

Group I: AB521 - Sequence CABExperimental Treatment1 Intervention

Participants will sequentially receive Treatment C, followed by Treatment A, then Treatment B

Group II: AB521 - Sequence BCAExperimental Treatment1 Intervention

Participants will sequentially receive Treatment B, followed by Treatment C, then Treatment A

Group III: AB521 - Sequence ABCExperimental Treatment1 Intervention

Participants will sequentially receive AB521 capsules fasted (Treatment A), followed by AB521 tablets fasted (Treatment B), followed by AB521 tablets fed (Treatment C)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

AB521

2023

Completed Phase 1

~100

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Arcus Biosciences, Inc.Lead Sponsor

41 Previous Clinical Trials

6,042 Total Patients Enrolled

Medical DirectorStudy DirectorArcus Biosciences

2,777 Previous Clinical Trials

8,063,456 Total Patients Enrolled

Media Library

AB521 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05999513 — Phase 1

Healthy Subjects Research Study Groups: AB521 - Sequence BCA, AB521 - Sequence CAB, AB521 - Sequence ABC

Healthy Subjects Clinical Trial 2023: AB521 Highlights & Side Effects. Trial Name: NCT05999513 — Phase 1

AB521 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05999513 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age limit for this trial inclusive of persons over 45 years?

"As specified in the study's requirements, participants must be aged between 19 and 55 to qualify for enrollment."

Answered by AI

Would I be eligible to participate in this experiment?

"For consideration in this medical trial, participants should be of sound health and between 19 and 55 years old. To complete the study, 24 individuals need to join."

Answered by AI

Are there currently any opportunities to join this research project?

"As verified on clinicaltrials.gov, this research is in search of participants as it was recently updated on August 14th 2023 and initially posted 8/22/2023."

Answered by AI

How detrimental is the AB521 - Sequence ABC for human beings?

"Our team at Power rated AB521 - Sequence ABC a score of 1 due to the limited clinical data gathered in its Phase 1 trial, which does not currently support safety or efficacy."

Answered by AI

What is the enrollment capacity of this medical trial?

"Affirmative. Per the information held on clinicaltrials.gov, this experiment is actively seeking volunteers for participation; first posted August 22nd 2023 and last modified August 14th 2023. The trial requires 24 individuals to be enrolled at one location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

2023. "A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05999513.

All > Omaha